EconPapers    
Economics at your fingertips  
 

A Likelihood-Based Approach for the Analysis of Longitudinal Clinical Trials with Return-to-Baseline Imputation

Yilong Zhang, Gregory Golm and Guanghan Liu ()
Additional contact information
Yilong Zhang: Merck & Co., Inc.
Gregory Golm: Merck & Co., Inc.
Guanghan Liu: Merck & Co., Inc.

Statistics in Biosciences, 2020, vol. 12, issue 1, No 2, 23-36

Abstract: Abstract Discontinuation of assigned therapy in longitudinal clinical trials is often inevitable due to various reasons such as intolerability or lack of efficacy. When the primary outcome of interest is the mean difference between treatment groups at the end of the trial, how to deal with the missing data due to discontinuation of assigned therapy is critical. The draft ICH E9 (R1) addendum proposes several strategies for handling intercurrent events, such as discontinuation of assigned therapy, under the estimand framework. The “hypothetical strategy”, in which the outcomes after discontinuation are envisioned under the hypothetical condition that patients who discontinued assigned therapy had actually stayed on assigned therapy, is commonly employed but requires untestable assumptions about the distribution of the post-discontinuation data. Return-to-baseline (RTB) is an assumption recently suggested by at least one regulatory agency. RTB assumes that any treatment effects observed prior to discontinuation are washed out, such that the mean effect at the end of the study among discontinued patients is the same as that at baseline. Multiple imputation (MI) may be used to implement this method but may overestimate the variance. In this paper, we propose a likelihood-based method to get the point estimate and variance for the treatment difference directly from a mixed-model for repeated measures (MMRM) analysis. Simulations are conducted to evaluate its performance as compared to other approaches including MI and MI with bootstrap. Two clinical trials are used to demonstrate the application.

Keywords: Missing data; Longitudinal clinical trials; Return-to-baseline; BOCF; Multiple imputation (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s12561-020-09269-0 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:stabio:v:12:y:2020:i:1:d:10.1007_s12561-020-09269-0

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/12561

DOI: 10.1007/s12561-020-09269-0

Access Statistics for this article

Statistics in Biosciences is currently edited by Hongyu Zhao and Xihong Lin

More articles in Statistics in Biosciences from Springer, International Chinese Statistical Association
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-03-20
Handle: RePEc:spr:stabio:v:12:y:2020:i:1:d:10.1007_s12561-020-09269-0